RNS Number : 1786R Hemogenyx Pharmaceuticals PLC 28 February 2023

28 February 2023

## Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

## **Total Voting Rights**

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 February 2022 consists of 1,141,999,321 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,141,999,321.

The figure of 1,141,999,321 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment in, or a change in their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

## **Enquiries:**

Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Peter Redmond, Director	https://hemogenyx.com headquarters@hemogenyx.com peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Matthew Johnson, Vadim Alexandre, Adam Cowl	Tel: +44 (0)20 3470 0470
Peterhouse Capital Limited Lucy Williams, Duncan Vasey, Charles Goodfellow	Tel: +44 (0)20 7469 0930

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

TVREAAAXALXDEFA